



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Secretary

July 12, 2017

Kenneth S. Reinker, Esq.
Counsel for Mallinckrodt plc
Cleary Gottlieb Steen & Hamilton LLP
2000 Pennsylvania Avenue, N.W.
Washington, D.C. 20006-1801

Re: Stipulated Order for Permanent Injunction and Equitable Monetary Relief, *FTC v. Mallinckrodt ARD, Inc. and Mallinckrodt plc*, No. 1:17-cv-120 (D.D.C. Jan. 30, 2017); FTC File No. 131 0172; FTC Matter No. X170029

Dear Mr. Reinker:

This is in reference to the Application for Approval of Proposed Synacthen Sublicense (“Application”) filed by Mallinckrodt ARD, Inc. and Mallinckrodt plc (collectively, “Mallinckrodt”) and received on June 30, 2017. Pursuant to the Stipulated Order for Permanent Injunction and Equitable Monetary Relief (“Order”) in this matter, Mallinckrodt requests that the Commission approve its proposed Synacthen Sublicense by and between Mallinckrodt and West Therapeutic Development, LLC (“West”).

After consideration of Mallinckrodt’s Application and other available information, the Commission has approved the proposed Synacthen Sublicense to West as required by the Synacthen Sublicense and Order. In according its approval, the Commission has relied upon the information submitted and the representations made by Mallinckrodt in connection with Mallinckrodt’s Application and has assumed them to be accurate and complete.

By direction of the Commission.

April J. Tabor
Acting Secretary

cc: Paul Reinfelds
Vice President - Legal Affairs and General Counsel
West Therapeutic Development, LLC
540 Ziegler Drive
Grayslake, IL 60030